Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention.

Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention. Abstract Text:

Franca Fruzzetti,Veronica Lazzarini,Cabiria Ricci,Barbara Quirici,Marco Gambacciani,Anna Maria Paoletti,Andrea Riccardo Genazzani,Franca Fruzzetti,Veronica Lazzarini,Cabiria Ricci,Barbara Quirici,Marco Gambacciani,Anna Maria Paoletti,Andrea Riccardo Genazzani,

PURPOSE: This study was conducted to evaluate body weight and composition during oral contraception with 30 microg ethinylestradiol plus 3 mg drospirenone (30EE+DRSP) in women affected by premenstrual syndrome (PMS) with somatic symptoms related to water retention. DESIGN: This prospective study was performed using multifrequency bioelectrical impedance analysis in 18 normally cycling PMS patients (mean age, 28.8 years) evaluated at baseline, during the luteal phase of the menstrual cycle and after 3 and 6 cycles of 30EE+DRSP. Total body water (TBW), intracellular water (ICW), extracellular water (ECW), fat mass and fat-free mass were evaluated. Body weight, waist-to-hip ratio and blood pressure were also determined at each visit. Basal values were compared with those measured in 31 healthy females without PMS (controls). RESULTS: PMS patients have higher levels of TBW and ICW than controls. After 6 months of 30EE+DRSP, TBW and ECW were significantly lower than before treatment. No significant variations in ICW or in the other parameters were observed. CONCLUSION: In women with PMS, 30EE+DRSP reduces the concentrations in TBW and ECW. This effect is likely due to the antimineralocorticoid activity of DRSP. Whether these changes may account for the improvement of premenstrual fluid-related symptoms reported with this formulation is discussed.

Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention. Publishing Authors By Initials

F Fruzzetti,V Lazzarini,C Ricci,B Quirici,M Gambacciani,AM Paoletti,AR Genazzani,F Fruzzetti,V Lazzarini,C Ricci,B Quirici,M Gambacciani,AM Paoletti,AR Genazzani,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Contraception

VOLUME: 76

Page Numbers: 190-4

Journal Abbreviation:

ISSN: 0010-7824

DAY: 20

MONTH: 07

YEAR: 2007

Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 234361

Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention.

AFFILIATION: Department of Obstetrics and Gynecology, University of Pisa, Via Roma 67, 56100 Pisa, Italy. ffruzzi@tin.it

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Contraception

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention Related Publications

• 5-hydroxytryptamine(1B) receptor and triptan response in migraine, lack of association with common polymorphisms.
• A case of acro-cephalo-syndactylia [Hebrew text].
• Biochemical prognostic factors and risk of relapses in patients with cervical cancer.
• Brain derived neurotrophic factor circulating levels in patients undergoing IVF.
• Brain recurrences in patients with ovarian cancer: report of 12 cases and review of the literature.
• CSF beta-EP in headache and depression.
• Calcineurin primes immature gonadotropin-releasing hormone-secreting neuroendocrine cells for migration.
• Characterization of NAD Uptake in Mammalian Cells.
• Circadian variations of proopiocortin-related peptides in children with migraine.
• Click chemistry reactions in medicinal chemistry: Applications of the 1,3-dipolar cycloaddition between azides and alkynes.
• Comparative effects of dydrogesterone and medroxyprogesterone acetate in critical areas: The brain and the vessels.
• Correlation of recurrence rates and times with posttreatment human papillomavirus status in patients treated with loop electrosurgical excision procedure conization for cervical squamous intraepithelial lesions.
• Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention.
• Endogenous opioid inhibitory tone on LH secretion in normal puberty and in several pubertal disturbances.
• Endorphin patterns within the headache spectrum disorders.
• Evaluation of central opioid tonus in menstrual migraine.
• Functional hypothalamic amenorrhea: Current view on neuroendocrine aberrations.
• Involvement of serotonin in the central control of opioid secretion.
• Naloxone test in primary headache sufferers.
• Neuroendocrine effects of flunarizine treatment in postmenopausal women.
• Opioid control of the hypothalamus-pituitary-adrenal axis cyclically fails in menstrual migraine.
• P26.08: Bilateral hemorrhagic fetal ovarian cyst: a case report.
• P26.12: Prenatal sonographic features of chloride diarrhea.
• Primary headaches: reduced circulating beta-lipotropin and beta-endorphin levels with impaired reactivity to acupuncture.
• Reduced testosterone levels in cluster headache: a stress-related phenomenon?
• Sympathergic/neuroendocrine reactivity as a marker of adaptive processes underlying migraine susceptibility.
• The association of menstrual migraine with the premenstrual syndrome.
• The management of patients with uterine sarcoma: A debated clinical challenge.
• The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: A review of the literature.
• Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women.